Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirukumab in Polymyalgia Rheumatica
NCT02899026Phase 3Withdrawn
- Sponsor
- GSK
- Start
- Mar 2018
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of sirukumab in polymyalgia rheumatica (PMR), sponsored by GSK. Planned start Mar 2018; status: withdrawn.
02
Drugs
sirukumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT02899026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02899026.